Shares of biotech company Sarepta Therapeutics (NASDAQ:SRPT) fell 24.9% in the pre-market session after the company reported ...

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

12 analysts have shared their evaluations of Sarepta Therapeutics (NASDAQ:SRPT) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...

Among these, Sarepta Therapeutics crashed following a report of a patient's death after treatment with Elevidys. Incyte also declined after study data disappointed investors. Shares of Sarepta ...

Sarepta Therapeutics SRPT shares soared 8.7% in the last trading session to close at $79.97. The move was backed by solid volume with far more shares changing hands than in a normal session.

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Sarepta Therapeutics (BMV:SRPT) with a Sector Perform recommendation. There are 956 funds or institutions reporting positions ...

In the last three months, 8 analysts have published ratings on Sarepta Therapeutics (NASDAQ:SRPT), offering a diverse range of perspectives from bullish to bearish. The table below offers a ...

Sarepta Therapeutics (SRPT) came out with quarterly earnings of $1.50 per share, missing the Zacks Consensus Estimate of $1.87 per share. This compares to earnings of $0.47 per share a year ago.

SAREPTA THERAPEUTICS ($SRPT) posted quarterly earnings results on Wednesday, February 26th. The company reported earnings of $1.50 per share, missing estimates of $1. ...

Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Sarepta Therapeutics (NasdaqGS:SRPT) with a Sector Perform recommendation. As of March 3, 2025, the average one-year price ...

In trading on Tuesday, shares of Sarepta Therapeutics Inc (Symbol: SRPT) entered into oversold territory, hitting an RSI reading of 29.4, after changing hands as low as $103.6733 per share.